Decoy Therapeutics (NASDAQ:DCOY) Trading Up 4.3% – Still a Buy?

Decoy Therapeutics (NASDAQ:DCOY) shares rose 4.3% during mid-day trading on Tuesday . The stock traded as high as $3.71 and last traded at $3.67. Approximately 26,566 shares were traded during trading, a decline of 69% from the average daily volume of 85,117 shares. The stock had previously closed at $3.52.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Trading Up 4.3%

The company has a market capitalization of $2.17 million, a P/E ratio of -0.12 and a beta of 0.64. The business’s 50-day simple moving average is $5.38 and its 200 day simple moving average is $6.49.

Decoy Therapeutics (NASDAQ:DCOY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($4.46) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter. As a group, sell-side analysts predict that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.